Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
We aspire to help patients and clinicians confront the most challenging cancers in modern medicine
Kazia’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer, which are poorly served by existing therapies
Click here
to access resources for patients
If you are a Kazia shareholder and want information on how to convert your unlisted shares to ADSs, please click on the link below.
Click here
We draw on the best research available, and partner with the world’s leading experts in cancer treatment
Kazia’s unique strength lies in the ability to identify promising undervalued drug candidates around the world, and to collaborate with researchers to discover and develop their potential
Click here
to access resources for partners
News
More News
Media
More Media
Presentations
More Presentations
Stock Information
Symbol
ASX:
Price
Change
(
)
Volume
Low / High
/
Market Cap
Stock Information
Symbol
NASDAQ:
Price
Change
(
)
Volume
Low / High
/
Market Cap